Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience
Submitted: November 14, 2016
Accepted: January 11, 2017
Published: December 31, 2017
Accepted: January 11, 2017
Abstract Views: 1446
PDF: 763
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
CUrA, Nuova Villa Claudia Clinic, Rome, Italy.
CUrA, Nuova Villa Claudia Clinic, Rome, Italy.
CUrA, Nuova Villa Claudia Clinic, Rome, Italy.
CUrA, Nuova Villa Claudia Clinic, Rome, Italy.
CUrA, Nuova Villa Claudia Clinic, Rome, Italy.
CUrA, Nuova Villa Claudia Clinic, Rome, Italy.
Campus Biomedico, Rome, Italy.
Villa Gioia Clinic, Sora (Fr), Italy.
How to Cite
Giulianelli, R., Gentile, B. C., Mirabile, G., Albanesi, L., Tariciotti, P., Rizzo, G., Buscarini, M., & Vermiglio, M. (2017). Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience. Archivio Italiano Di Urologia E Andrologia, 89(4), 272–276. https://doi.org/10.4081/aiua.2017.4.272
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.